Forte Biosciences (FBRX) Enterprise Value (2016 - 2026)
Forte Biosciences (FBRX) reported Enterprise Value of -$58.2 million for Q1 2026, down 26.97% year-over-year from -$79.7 million in Q1 2025, and up 24.34% quarter-over-quarter from -$77.0 million in Q4 2025.
Forte Biosciences (FBRX) Enterprise Value (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Enterprise Value data on file, last reported at -$58.2 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$58.2 million, down 26.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$58.2 million (down 26.97% YoY), and the FY2025 annual result was -$77.0 million, down 31.85% from the prior year.
- Enterprise Value advanced to -$58.2 million in Q1 2026 per FBRX's latest filing, from -$77.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$16.4 million in Q3 2024 and troughed at -$106.1 million in Q2 2025.
- A 5-year average of -$48.4 million and a median of -$41.1 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 64.5% in 2024, then sank 469.51% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$41.1 million in 2022, then increased by 9.67% to -$37.1 million in 2023, then tumbled by 57.21% to -$58.4 million in 2024, then sank by 31.85% to -$77.0 million in 2025, then grew by 24.34% to -$58.2 million in 2026.
- Business Quant data shows FBRX's Enterprise Value at -$58.2 million in Q1 2026, -$77.0 million in Q4 2025, and -$93.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -58.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.22 Mn |
| Dec 31, 2025 | -76.96 Mn |
| Sep 30, 2025 | -93.40 Mn |
| Jun 30, 2025 | -106.10 Mn |
| Mar 31, 2025 | -45.86 Mn |
| Dec 31, 2024 | -58.37 Mn |
| Sep 30, 2024 | -16.40 Mn |
| Jun 30, 2024 | -24.50 Mn |
| Mar 31, 2024 | -30.40 Mn |
| Dec 31, 2023 | -37.13 Mn |
| Sep 30, 2023 | -46.20 Mn |
| Jun 30, 2023 | -30.43 Mn |
| Mar 31, 2023 | -35.90 Mn |
| Dec 31, 2022 | -41.10 Mn |
| Sep 30, 2022 | -44.05 Mn |
| Jun 30, 2022 | -38.55 Mn |
| Mar 31, 2022 | -40.00 Mn |
| Dec 31, 2021 | -42.04 Mn |
| Sep 30, 2021 | -45.70 Mn |
| Jun 30, 2021 | -50.80 Mn |